Status:
RECRUITING
Isolation of Human Recombinant Therapeutic Monoclonal Anti-Pseudomonas Antibodies
Lead Sponsor:
University Hospital, Grenoble
Conditions:
Pseudomonas Aeruginosa
Multi-antibiotic Resistance
Eligibility:
All Genders
18+ years
Brief Summary
Pseudomonas aeruginosa is a pathogenic bacteria for human, especially in hospital settings. It can sometimes be multi-resistant to many or even to all antibiotics usually used for its treatment. The ...
Eligibility Criteria
Inclusion
- Patient selected in the retrospective part of the study (patient with serum containing functional anti-Pseudomonas aeruginosa antibodies)
- Patient with weight ≥ 32kg.
- With a follow-up visit at Grenoble University Hospital with a blood sampling for its care
- Having given its written no objection to participate in the prospective phase of this project
Exclusion
- Legally protected patient (minor, pregnant or nursing woman, ward or ward curated, hospitalized under duress or deprived of liberty)
Key Trial Info
Start Date :
October 5 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2026
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04335383
Start Date
October 5 2020
End Date
October 1 2026
Last Update
November 20 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chu Grenoble Alpes
Grenoble, France, 38043